# Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)

Study · id `cardio:ct-nct02360956` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02360956](<https://clinicaltrials.gov/study/NCT02360956>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02360956

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02360956. Randomized; single masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02360956, source copy `cardio:ctgov-nct02360956-2015-02-11`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02360956, source copy `cardio:ctgov-nct02360956-2015-02-11`, retrieved 2026-10-26)
- Primary completion: 2016-06 (anticipated) (ClinicalTrials.gov record NCT02360956, source copy `cardio:ctgov-nct02360956-2015-02-11`, retrieved 2026-10-26)
- Completion: 2016-06 (anticipated) (ClinicalTrials.gov record NCT02360956, source copy `cardio:ctgov-nct02360956-2015-02-11`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02360956, source copy `cardio:ctgov-nct02360956-2015-02-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02360956-2015-02-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)
- Condition: Coronary Atherosclerosis
- Intervention (Drug): Olmesartan medoxomil tablets
- Intervention (Drug): Antihypertensive medication (per doctor suggestion)
- Lead sponsor: Chinese PLA General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)

## Provenance

Content hash: 26f3ad21a78d8f50dd2d802226ce53a9738ef98d61444d174b0cf29d39b4fc9a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
